NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Renova Therapeutics

Renova Therapeutics

Private
Carlsbad, CaliforniaHealthcare & Life Scienceshttps://renovatherapeutics.com/

Last Round

Grant

Jun 1, 2022

Total Funding Raised

$9.12M

Company Overview

Renova Therapeutics is a biotechnology company that develops definitive, one-time gene therapies to restore the health of people suffering from chronic diseases such as congestive heart failure and type 2 diabetes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

gene therapycongestive heart failuresingle-dose gene therapycardiovascular diseaseclinical-stage biotechnologyAC6 gene therapyreduced ejection fractionHFrEFadenovirus vectortype 2 diabetesmetabolic diseaseone and done therapyviral vector therapypeptide therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Renova Therapeutics Comparables

Compare Renova Therapeutics with similar companies based on industry and business-model similarity.

Renova Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Medera
83%
Bayer AG
80%
XyloCor Therapeutics
77%

Renova Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 1, 2022
GrantFeb 23, 2016
Series CSep 30, 2014

Key People

Founding team and executive leadership

Jack Reich

Chief Executive Officer

Executive Team

Vijay Mahant

President And CEO

Executive Team

Renova Therapeutics Investors

Notable investors and investment history

Renova Therapeutics investors
InvestorRounds
NIH RADxGrant
National Heart, Lung, and Blood InstituteGrant
BioBritSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 2, 2025

    Monthly visitors grew 36% MoM, reaching 1.9K.

  • May 2, 2025

    Monthly visitors grew 33% MoM, reaching 1.6K.

Renova Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Renova Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Renova Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCarlsbad, California
Employee Range7
Year Founded2009
Last FundingJun 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.